Valuation: Shield Therapeutics plc

Market Cap 40.66M 54.98M 47.59M 44.48M 76.61M 5.24B 77.81M 522M 205M 2.62B 206M 202M 8.74B P/E 2026 *
-173x
P/E 2027 * 5.15x
Enterprise Value 58.98M 79.75M 69.04M 64.53M 111M 7.61B 113M 757M 297M 3.81B 299M 293M 12.67B EV / Sales 2026 *
1.05x
EV / Sales 2027 * 0.68x
Free-Float
38.25%
Yield 2026 *
-
Yield 2027 * -
1 day+1.32%
1 week-2.53%
Current month-2.53%
1 month-39.84%
3 months-45.00%
6 months-64.19%
Current year-60.91%
1 week 3.7
Extreme 3.7
4.1
1 month 3.7
Extreme 3.7
6.5
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 23/07/2024
Investor Relations Contact - -
General Counsel - 31/12/2025
Director TitleAgeSince
Chairman 70 17/06/2020
Director/Board Member 68 31/01/2016
Director/Board Member 59 09/05/2021
Date Insider Type Main position Quantity % Market Cap.
14/10/25 Free

Chief Executive Officer

1,547,262 0.1485%
13/02/25 Free

Chief Executive Officer

5,000,000 0.4800%
13/02/25 Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
+1.32%-2.53%-16.30%-65.78% 54.87M
+2.70%+5.24%+46.35%+0.75% 78.32B
+0.84%+5.66%-0.15%+27.88% 51.1B
+0.90%+1.67%+20.63%+176.54% 49.18B
+1.72%+9.27%-48.46%-48.80% 44.71B
-0.37%+2.61%+61.78%-23.04% 30.72B
+1.09%+2.91%+53.91%+86.05% 24.44B
+0.32%+7.93%+133.65%-40.66% 23.62B
+2.58%+12.23%+6.63%+202.17% 21.05B
-0.62%+3.30%+64.98%+114.68% 16.61B
Average +1.12%+2.98%+32.30%+42.98% 33.98B
Weighted average by Cap. +1.31%+3.83%+29.61%+42.89%

Financials

2026 *2027 *
Net sales 56.28M 76.1M 65.88M 61.58M 106M 7.26B 108M 722M 283M 3.63B 286M 280M 12.09B 75.86M 103M 88.8M 83M 143M 9.78B 145M 973M 382M 4.89B 385M 377M 16.3B
Net income -72.5K -98.03K -84.87K -79.33K -137K -9.35M -139K -930K -365K -4.68M -368K -360K -15.58M 7.86M 10.63M 9.2M 8.6M 14.81M 1.01B 15.04M 101M 39.57M 507M 39.91M 39.03M 1.69B
Net Debt 18.32M 24.77M 21.45M 20.05M 34.53M 2.36B 35.07M 235M 92.24M 1.18B 93.03M 91M 3.94B 11.13M 15.05M 13.03M 12.18M 20.98M 1.44B 21.31M 143M 56.05M 718M 56.52M 55.29M 2.39B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
10/08/26 GBX 3.850 +1.32% 1,369,051
07/08/26 GBX 3.800 -1.30% 1,146,599
06/08/26 GBX 3.850 -3.75% 800,205
05/08/26 GBX 4.000 +8.11% 3,530,795
04/08/26 GBX 3.700 -6.33% 5,191,786
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0380GBP
Average target price
0.1667GBP
Spread / Average Target
+338.61%

Annual profits - Rate of surprise